New cocktail aims to knock out leukemia for good
NCT ID NCT01496976
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a combination of three drugs—ofatumumab, high-dose methylprednisolone, and lenalidomide—in 45 people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if this approach could make all signs of cancer disappear and keep it away for a long time. Participants first received ofatumumab and steroids, then a consolidative phase with ofatumumab and lenalidomide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ofatumumab, high-dose methylprednisolone, and lenalidomide
- What this could lead to
- If successful, this combination could offer a long-lasting treatment option for people with untreated CLL/SLL, potentially keeping the cancer in remission for years.
- What could go wrong
- This is a small, early-phase trial (45 participants) with no control group, so results may not apply to everyone. The drugs can cause serious side effects like infections, blood clots, and nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?